RARE — Ultragenyx Pharmaceutical Inc.

Is RARE overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Neutral As of November 17, 2026

Ultragenyx Pharmaceutical Inc. (RARE) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $15.90. The rating moved from Overbought to Neutral on November 17, 2026.

AI analysis

Ultragenyx is a rare-disease biotechnology company with commercial products that provide revenue stability alongside a portfolio of higher-risk/high-reward development programs, including gene therapies. The company benefits from specialty distribution channels and could be an attractive partner or acquisition target in a sector seeing consolidation, but it remains exposed to binary clinical outcomes, potential dilution, and payer/regulatory headwinds. Near-term price action will likely track broader risk appetite and any clinical or corporate-development headlines; medium-term upside depends on successful readouts, partnership execution, or M&A interest.

Key factors

  • Established commercial rare-disease products providing recurring revenue and near-term cash flow support
  • Pipeline of gene therapy and specialty biologic programs with meaningful upside if clinical/readout successes occur
  • Balance sheet likely supports near-term operations but late-stage programs may require additional financing or partnerships
  • Sector-wide consolidation and large-cap pharma interest in specialty/rare assets create potential M&A or partnership upside
  • Current market tone is risk-off with defensive flows into large-cap pharma, reducing appetite for small/biotech outperformance in the near term
  • Distributor and specialty pharmacy tailwinds for chronic injectable/specialty therapies could support commercial channels for certain assets

Risks

  • Clinical trial failures, negative readouts or safety issues for pipeline candidates that would materially impair valuation
  • High cash burn and the potential for equity dilution or unfavorable financing if capital is needed for late-stage programs
  • Reimbursement, pricing scrutiny and regulatory changes (including tighter Medicare/MA program integrity) that could pressure pricing or access
  • Competition from larger, better-capitalized pharma/biotech players and potential erosion of market share in certain indications
  • Regulatory approval delays or additional data requirements that push timelines and increase cost
  • Broader market volatility and risk-off investor behavior that disproportionately impacts small-cap biopharma shares

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for RARE — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.